Nuclear Matrix Protein 2 Antibody-positive Dermatomyositis Associated with Hepatocellular Carcinoma
Overview
Overview
Journal
Rheumatol Adv Pract
Publisher
Oxford University Press
Specialty
Rheumatology
Date
2023 Aug 11
PMID
37564124
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Han J, Wang S, Kwong T, Liu J
. Dermatomyositis as an extrahepatic manifestation of hepatitis B virus-related hepatocellular carcinoma: A case report and literature review. Medicine (Baltimore). 2018; 97(33):e11586.
PMC: 6113031.
DOI: 10.1097/MD.0000000000011586.
View
2.
Abe S, Tsuboi H, Toko H, Honda F, Yagishita M, Hagiwara S
. Clinically amyopathic dermatomyositis associated with anti-nuclear matrix protein 2 antibody. Rheumatol Adv Pract. 2022; 5(3):rkab104.
PMC: 8710850.
DOI: 10.1093/rap/rkab104.
View
3.
Fiorentino D, Chung L, Christopher-Stine L, Zaba L, Li S, Mammen A
. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013; 65(11):2954-62.
PMC: 4073292.
DOI: 10.1002/art.38093.
View
4.
Rider L, Shah M, Mamyrova G, Huber A, Rice M, Targoff I
. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013; 92(4):223-243.
PMC: 3721421.
DOI: 10.1097/MD.0b013e31829d08f9.
View
5.
Tanboon J, Inoue M, Saito Y, Tachimori H, Hayashi S, Noguchi S
. Dermatomyositis: Muscle Pathology According to Antibody Subtypes. Neurology. 2021; 98(7):e739-e749.
PMC: 8865893.
DOI: 10.1212/WNL.0000000000013176.
View